scispace - formally typeset
Open AccessJournal ArticleDOI

Ataxin-2 gene: a powerful modulator of neurological disorders.

TLDR
The role of ATXN2 and its variants in association with SCA2 and several other neurological diseases has been discussed in this paper, including motor neuron disease, spinocerebellar ataxia 3 (SCA3), and familial amyloidosis polyneuropathy.
Abstract
Purpose of review To provide an update on the role of Ataxin-2 gene (ATXN2) in health and neurological diseases. Recent findings There is a growing complexity emerging on the role of ATXN2 and its variants in association with SCA2 and several other neurological diseases. Polymorphisms and intermediate cytosine adenine guanine alleles in ATXN2 establish this gene as a powerful modulator of neurological diseases including lethal neurodegenerative conditions such as motor neuron disease, spinocerebellar ataxia 3 (SCA3), and peripheral nerve disease such as familial amyloidosis polyneuropathy. This role is in fact far wider than the previously described for polymorphism in the prion protein (PRNP) gene. Positive data from antisense oligo therapy in a murine model of SCA2 suggest that similar approaches may be feasible in humans SCA2 patients. Summary ATXN2 is one of the few genes where a single gene causes several diseases and/or modifies several and disparate neurological disorders. Hence, understanding mutagenesis, genetic variants, and biological functions will help managing SCA2, and several human diseases connected with dysfunctional pathways in the brain, innate immunity, autophagy, cellular, lipid, and RNA metabolism.

read more

Citations
More filters
Journal ArticleDOI

Insights from analyses of low complexity regions with canonical methods for protein sequence comparison

TL;DR: The existing methods for similarity analysis of low complexity regions using BLAST, HHblits and CD-HIT are investigated in order to understand how they can be applied to compare such regions.
Journal ArticleDOI

Antisense oligonucleotides targeting basal forebrain ATXN2 enhances spatial memory and ameliorates sleep deprivation‐induced fear memory impairment in mice

TL;DR: In this article , Antisense oligonucleotides (ASOs) targeting ATXN2 were used as a potential therapy for spinocerebellar ataxia, whose pathogenic mechanism associates with reduced BDNF expression.
Journal ArticleDOI

Are ATXN2 variants modifying our understanding about neural pathogenesis, phenotypes, and diagnostic?

TL;DR: The ATXN2 gene encodes a cytosolic protein (ataxin-2) with pleiotropic functions (see below) which contains a number of exonic Cytosine-Adenine-Guanine (CAG)repeats which encode a polyglutamine tract (polyQ) in the N-terminal intrinsically disordered region (IDR) of the protein.
Journal ArticleDOI

TR-FRET-Based Immunoassay to Measure Ataxin-2 as a Target Engagement Marker in Spinocerebellar Ataxia Type 2

TL;DR: In this paper , the amount of soluble polyQ-expanded ataxin-2 in human biofluids was measured using time-resolved fluorescence energy transfer (TR-FRET) and validated measurements in human cell lines including iPSC-derived cortical neurons.
References
More filters
Journal ArticleDOI

Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT.

TL;DR: A novel strategy, the direct identification of repeat expansion and cloning technique (DIRECT), which allows selective detection of expanded GAG repeats and cloning of the genes involved and will dramatically accelerate the search for causative genes of neuropsychiatric diseases caused by trinucleotide repeat expansions.
Journal ArticleDOI

An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease

TL;DR: A workgroup commissioned by the Alzheimer's Association and the National Institute on Aging recently published research criteria for preclinical Alzheimer disease (AD) performed a preliminary assessment of these guidelines.
Journal ArticleDOI

Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis

Jonathan D. Rohrer, +63 more
- 01 Mar 2015 - 
TL;DR: Structural imaging and cognitive changes can be identified 5-10 years before expected onset of symptoms in asymptomatic adults at risk of genetic frontotemporal dementia, which could help to define biomarkers that can stage presymPTomatic disease and track disease progression.
Related Papers (5)